Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy

Tumor Biology

Volumn 33, Issue 1, 2012, Pages 33-40

  Kohles, Nikolaus ^a   Nagel, Dorothea ^a   Jüngst, Dietrich ^a   Durner, Jürgen ^a   Stieber, Petra ^a   Holdenrieder, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cell death marker; Hepatocellular cancer; Oncologic biomarkers; Prognosis; Serum; Transarterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CHOLINESTERASE; CYTOKERATIN 19 FRAGMENT; LACTATE DEHYDROGENASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

EID: 83655203397     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0237-7     Document Type: Article

References (32)

1. C Hellerbrand A Hartmann G Richter A Knoll R Wiest J Scholmerich, et al. 2001 Hepatocellular carcinoma in southern Germany: epidemiological and clinicopathological characteristics and risk factors Digest Dis 19 345 351 10.1159/000050702 1:STN:280:DC%2BD383gtF2ltg%3D%3D (Pubitemid 34298003)
2. H Tsukuma T Hiyama S Tanaka M Nakao T Yabuuchi T Kitamura, et al. 1993 Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1797 1801 7684822 10.1056/NEJM199306243282501 1:STN:280:DyaK3s3nsFektg%3D%3D (Pubitemid 23174709)
3. RF Velazquez M Rodriguez CA Navascues A Linares R Perez NG Sotorrios, et al. 1993 Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis Hepatol 37 520 527 10.1053/jhep.2003.50093
4. DM Parkin F Bray J Ferlay P Pisani 2001 Estimating the world cancer burden: GLOBOCAN 2000 Int J Cancer 94 153 156 11668491 10.1002/ijc.1440 1:CAS:528:DC%2BD3MXntVGlu78%3D (Pubitemid 32911406)
5. HB El-Serag AC Mason 1999 Hepatocellular carcinoma is rising in the United States Gastroenterol 116 G0235 10.1016/S0016-5085(99)70115-0
6. HB El-Serag JA Marrero L Rudolph KR Reddy 2008 Diagnosis and treatment of hepatocellular carcinoma Gastroenterol 134 1752 1763 10.1053/j.gastro.2008.02. 090 (Pubitemid 351615415)
7. A Forner AJ Hessheimer MI Real J Bruix 2006 Treatment of hepatocellular carcinoma Crit Rev Oncol Hematol 60 89 98 16860993 10.1016/j.critrevonc.2006.06. 001 (Pubitemid 44740494)
8. J Bruix JM Llovet A Castells X Montana C Bru MD Ayuso, et al. 1998 Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution Hepatol 27 1578 1583 10.1002/hep.510270617 1:STN:280:DyaK1c3otFKnsg%3D%3D (Pubitemid 28264682)
9. JM Llovet J Bruix 2003 Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatol 37 429 442 10.1053/jhep.2003.50047 1:CAS:528:DC%2BD3sXhsFeltrg%3D (Pubitemid 36152543)
10. JM Llovet MI Real X Montana R Planas S Coll J Aponte, et al. 2002 Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 1734 1739 12049862 10.1016/S0140-6736(02)08649-X (Pubitemid 34607087)
11. Anonymous 1995 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire N Engl J Med 332 1256 1261 10.1056/NEJM199505113321903
12. G Pelletier M Ducreux F Gay M Luboinski H Hagege T Dao, et al. 1998 Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial J Hepatol 29 129 134 9696501 10.1016/S0168-8278(98)80187-6 1:CAS:528:DyaK1cXmvVWhsLk%3D (Pubitemid 28307992)
13. K Takayasu S Arii I Ikao M Omata K Okita T Ichida, et al. 2006 Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients Gastroenterol 131 461 469 10.1053/j.gastro.2006.05.021 1:CAS:528:DC%2BD28XpsFyks7Y%3D (Pubitemid 44142456)
14. JSM Bruix JM Llovet 2004 Chemoembolization for hepatocellular carcinoma Gastroenterol 127 179 188 10.1053/j.gastro.2004.09.032 (Pubitemid 39423386)
15. HS Lim YY Jeong HK Kang JK Kim JG Park 2006 Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation Am J Roentgenol 187 W341 W349 10.2214/AJR.04.1932
16. K Takayasu S Arii N Matsuo M Yoshikawa M Ryu K Takasaki, et al. 2000 Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma Am J Roentgenol 175 699 704 1:STN:280:DC%2BD3cvnsFartA%3D%3D
17. A Thabet S Kalva DA Gervais 2009 Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response Abdom Imaging 34 593 609 19015913 10.1007/s00261-008-9448-9
18. S Holdenrieder P Stieber J von Pawel H Raith D Nagel K Feldmann, et al. 2006 Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments Ann N Y Acad Sci 1075 244 275 17108218 10.1196/annals.1368.033 1:CAS:528:DC%2BD28XhtFCqsLfJ (Pubitemid 44532791)
19. S Holdenrieder J von Pawel E Dankelmann T Duell B Faderl A Markus, et al. 2009 Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer Lung Cancer 63 128 135 18571761 10.1016/j.lungcan.2008.05.001
20. S Holdenrieder J von Pawel E Dankelmann T Duell B Faderl A Markus, et al. 2008 Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy Clin Cancer Res 14 7813 7821 19047109 10.1158/1078-0432.CCR-08-0678 1:CAS:528:DC%2BD1cXhsVegtrfL
21. J Bruix M Sherman JM Llovet M Beaugrand R Lencioni AK Burroughs, et al. 2001 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference J Hepatol 35 421 430 11592607 10.1016/S0168-8278(01)00130-1 1:STN:280:DC%2BD3MrksFCmtg%3D%3D (Pubitemid 32844200)
22. S Holdenrieder P Stieber H Bodenmuller G Fertig H Furst N Schmeller, et al. 2001 Nucleosomes in serum as a marker for cell death Clin Chem Lab Med 39 596 605 11522104 10.1515/CCLM.2001.095 1:CAS:528:DC%2BD3MXmslSmsr0%3D (Pubitemid 32725743)
23. TJ Vogl TJ Vogl NNN Naguib NEA Nour-Eldin P Rao AH Emami, et al. 2009 Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications Eur J Radiol 72 505 516 18835117 10.1016/j.ejrad.2008.08.007
24. RE Meyn LC Stephens KK Ang NR Hunter WA Brock L Milas, et al. 1993 Heterogeneity in the development of apoptosis in irradiated murine tumors of different histologies Int J Rad Biol 64 583 591 7902398 10.1080/ 09553009314551801 1:STN:280:DyaK2c%2FmsFChtQ%3D%3D (Pubitemid 23350460)
25. I Fabregat 2009 Dysregulation of apoptosis in hepatocellular carcinoma cells World J Gastroenterol 15 513 520 19195051 10.3748/wjg.15.513 1:CAS:528:DC%2BD1MXpsFCgtrg%3D
26. Z Jing KJ Nan ML Hu 2005 Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma World J Gastroenterol 11 1910 1916 15800979 1:CAS:528:DC%2BD2MXktFyrur0%3D (Pubitemid 40520985)
27. N Kohles D Jüngst J Durner D Nagel P Stieber S Holdenrieder 2011 Predictive value of circulating nucleosomes and oncological biomarkers in liver cancer patients undergoing transarterial chemoembolisation therapy BMC Cancer 11 202 21615953 10.1186/1471-2407-11-202 1:CAS:528:DC%2BC3MXmvFCrs7k%3D
28. N Ren QH Ye LX Qin BH Zhang YK Liu ZY Tang 2006 Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients World J Gastroenterol 12 3911 3914 16804981 1:CAS:528: DC%2BD28Xot1KitL4%3D (Pubitemid 44028408)
29. G Sozzi D Conte L Mariani S Lo Vullo L Roz C Lombardo, et al. 2001 Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients Cancer Res 61 4675 4678 11406535 1:CAS:528: DC%2BD3MXks1GrtL0%3D (Pubitemid 32691874)
30. O Gautschi C Bigosch B Huegli M Jermann A Marx E Chasse, et al. 2004 Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy J Clin Oncol 22 4157 4164 15483026 10.1200/JCO.2004.11.123 1:CAS:528:DC%2BD2cXpslOrsL4%3D (Pubitemid 41185186)
31. L Llado J Virgili J Figueras C Valls J Dominguez A Rafecas, et al. 2000 A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization Cancer 88 50 57 10618605 10.1002/(SICI)1097-0142(20000101)88:1<50::AID-CNCR8>3.0.CO;2-I 1:STN:280:DC%2BD3c%2Fos1Onsg%3D%3D (Pubitemid 30027678)
32. CB O'Suilleabhain RTP Poon JL Yong GC Ooi WK Tso ST Fan 2003 Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma Br J Surg 90 325 331 12594668 10.1002/bjs.4045 (Pubitemid 36324112)